Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022

ObjectiveTo analyze the failure of antiretroviral therapy (ART) and drug resistance characteristics among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022.MethodsBlood samples, sociodemographic characteristics and ART information of the newly reported HIV-infected patients...

Full description

Saved in:
Bibliographic Details
Main Authors: LI Yan, WU Xuanhe, SHI Lu, LI Guixia, WANG Shanling, WANG Yating, CHEN Tailin, WANG Tingting, XIE Yali, SHEN Weiwei, LIN Haijiang, CHEN Xiaoxiao, HE Na
Format: Article
Language:zho
Published: Shanghai Preventive Medicine Association 2024-11-01
Series:Shanghai yufang yixue
Subjects:
Online Access:http://www.sjpm.org.cn/article/doi/10.19428/j.cnki.sjpm.2024.23877?viewType=HTML
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590431692521472
author LI Yan
WU Xuanhe
SHI Lu
LI Guixia
WANG Shanling
WANG Yating
CHEN Tailin
WANG Tingting
XIE Yali
SHEN Weiwei
LIN Haijiang
CHEN Xiaoxiao
HE Na
author_facet LI Yan
WU Xuanhe
SHI Lu
LI Guixia
WANG Shanling
WANG Yating
CHEN Tailin
WANG Tingting
XIE Yali
SHEN Weiwei
LIN Haijiang
CHEN Xiaoxiao
HE Na
author_sort LI Yan
collection DOAJ
description ObjectiveTo analyze the failure of antiretroviral therapy (ART) and drug resistance characteristics among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022.MethodsBlood samples, sociodemographic characteristics and ART information of the newly reported HIV-infected patients who received ART for ≥6 months in Taizhou City from 2020 to 2022 were collected for the detection of recent infections and HIV-1 genotypic drug resistance. Multivariate logistic regression analysis was used to analyze the influencing factors of treatment failure. The gene sequences of cases with failed ART were submitted to the HIV drug resistance database of Stanford University to determine the drug resistance mutation sites and drug resistance characteristics.ResultsAmong the 1 023 newly reported HIV-infected patients receiving ART, the median age (P25,P75) was 47 (33, 58) years, 81.4% were male, 66.4% (679/1 023) were infected through heterosexual transmission, 74.7% had a WHO clinical stage Ⅰ/Ⅱ, 62.2% had a baseline CD4 count of >200 cell·μL-1, 94.4% (966/1 023) received an immediate ART, and 78.7% were long-term infected. Among the 66 patients with treatment failure (6.5%), the likelihood of treatment failure was lower in those with homosexual transmission (OR=0.39, 95%CI: 0.17‒0.84) and without history of sexually transmitted disease (STD) (OR=0.45, 95%CI: 0.24‒0.92), but higher in those with a baseline CD4 count of ≤200 cell·μL-1, delayed ART (OR=3.19, 95%CI: 1.24‒7.52), and primary drug resistance (OR=4.69, 95%CI: 1.68‒11.89). Among the 36 HIV-infected patients with virological failure, 27 sequences were successfully amplified, with a successful amplification rate of 75.0% (27/36). The total drug resistance rate was 55.6% (15/27), of which the drug resistance rates of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) were 37.0% (10/27), 51.9% (14/27) and 3.7% (1/27), respectively. Among the NNRTIs, the degree of resistance to efavirenz and nevirapine was consistent, with a majority (51.9%) of highly drug-resistant. K103N and M184V were the most common mutation sites, but PIs mutations occured less frequently. A total of 8 genotypes of HIV-1 were detected, in which subtype CRF01_AE accounted for 37.0% (10/27), followed by CRF07_BC [14.8% (4/27)], CRF08_BC [14.8% (4/27)] and subtype C [14.8% (4/27)].ConclusionDuring the period from 2020 to 2022, the newly reported HIV-infected individuals in Taizhou City were predominated by long-term infections. Immediate initiation of ART can reduce the risk of treatment failure in HIV-infected individuals. Virological treatment failures are primarily associated with resistance to NRTIs and NNRTIs. It is recommended to strengthen active detection and promptly initiate ART to minimize the occurrence of ART failure. Simultaneously, there is a need to intensify drug resistance detection targeted for those with treatment failure, so as to provide a scientific guidance for drug replacement.
format Article
id doaj-art-dd761a29f4e541b88af4cd34a3e16bee
institution Kabale University
issn 1004-9231
language zho
publishDate 2024-11-01
publisher Shanghai Preventive Medicine Association
record_format Article
series Shanghai yufang yixue
spelling doaj-art-dd761a29f4e541b88af4cd34a3e16bee2025-01-23T23:27:10ZzhoShanghai Preventive Medicine AssociationShanghai yufang yixue1004-92312024-11-0136111031103810.19428/j.cnki.sjpm.2024.238771004-9231(2024)11-1031-08Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022LI Yan0WU Xuanhe1SHI Lu2LI Guixia3WANG Shanling4WANG Yating5CHEN Tailin6WANG Tingting7XIE Yali8SHEN Weiwei9LIN Haijiang10CHEN Xiaoxiao11HE Na12Huangyan District Center for Disease Control and Prevention, Taizhou, Zhejiang318020, ChinaDepartment of Epidemiology, School of Public Health, Fudan University, Yiwu Research Institute of Fudan University, Shanghai200032, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaDepartment of Epidemiology, School of Public Health, Fudan University, Yiwu Research Institute of Fudan University, Shanghai200032, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaTaizhou Center for Disease Control and Prevention, Taizhou, Zhejiang318000, ChinaDepartment of Epidemiology, School of Public Health, Fudan University, Yiwu Research Institute of Fudan University, Shanghai200032, ChinaObjectiveTo analyze the failure of antiretroviral therapy (ART) and drug resistance characteristics among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022.MethodsBlood samples, sociodemographic characteristics and ART information of the newly reported HIV-infected patients who received ART for ≥6 months in Taizhou City from 2020 to 2022 were collected for the detection of recent infections and HIV-1 genotypic drug resistance. Multivariate logistic regression analysis was used to analyze the influencing factors of treatment failure. The gene sequences of cases with failed ART were submitted to the HIV drug resistance database of Stanford University to determine the drug resistance mutation sites and drug resistance characteristics.ResultsAmong the 1 023 newly reported HIV-infected patients receiving ART, the median age (P25,P75) was 47 (33, 58) years, 81.4% were male, 66.4% (679/1 023) were infected through heterosexual transmission, 74.7% had a WHO clinical stage Ⅰ/Ⅱ, 62.2% had a baseline CD4 count of >200 cell·μL-1, 94.4% (966/1 023) received an immediate ART, and 78.7% were long-term infected. Among the 66 patients with treatment failure (6.5%), the likelihood of treatment failure was lower in those with homosexual transmission (OR=0.39, 95%CI: 0.17‒0.84) and without history of sexually transmitted disease (STD) (OR=0.45, 95%CI: 0.24‒0.92), but higher in those with a baseline CD4 count of ≤200 cell·μL-1, delayed ART (OR=3.19, 95%CI: 1.24‒7.52), and primary drug resistance (OR=4.69, 95%CI: 1.68‒11.89). Among the 36 HIV-infected patients with virological failure, 27 sequences were successfully amplified, with a successful amplification rate of 75.0% (27/36). The total drug resistance rate was 55.6% (15/27), of which the drug resistance rates of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) were 37.0% (10/27), 51.9% (14/27) and 3.7% (1/27), respectively. Among the NNRTIs, the degree of resistance to efavirenz and nevirapine was consistent, with a majority (51.9%) of highly drug-resistant. K103N and M184V were the most common mutation sites, but PIs mutations occured less frequently. A total of 8 genotypes of HIV-1 were detected, in which subtype CRF01_AE accounted for 37.0% (10/27), followed by CRF07_BC [14.8% (4/27)], CRF08_BC [14.8% (4/27)] and subtype C [14.8% (4/27)].ConclusionDuring the period from 2020 to 2022, the newly reported HIV-infected individuals in Taizhou City were predominated by long-term infections. Immediate initiation of ART can reduce the risk of treatment failure in HIV-infected individuals. Virological treatment failures are primarily associated with resistance to NRTIs and NNRTIs. It is recommended to strengthen active detection and promptly initiate ART to minimize the occurrence of ART failure. Simultaneously, there is a need to intensify drug resistance detection targeted for those with treatment failure, so as to provide a scientific guidance for drug replacement.http://www.sjpm.org.cn/article/doi/10.19428/j.cnki.sjpm.2024.23877?viewType=HTMLhivrecent infectionantiretroviral therapy failureantiretroviral therapy strategygenotypic drug resistance
spellingShingle LI Yan
WU Xuanhe
SHI Lu
LI Guixia
WANG Shanling
WANG Yating
CHEN Tailin
WANG Tingting
XIE Yali
SHEN Weiwei
LIN Haijiang
CHEN Xiaoxiao
HE Na
Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
Shanghai yufang yixue
hiv
recent infection
antiretroviral therapy failure
antiretroviral therapy strategy
genotypic drug resistance
title Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
title_full Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
title_fullStr Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
title_full_unstemmed Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
title_short Treatment failure and drug resistance among the newly reported HIV-infected patients in Taizhou City from 2020 to 2022
title_sort treatment failure and drug resistance among the newly reported hiv infected patients in taizhou city from 2020 to 2022
topic hiv
recent infection
antiretroviral therapy failure
antiretroviral therapy strategy
genotypic drug resistance
url http://www.sjpm.org.cn/article/doi/10.19428/j.cnki.sjpm.2024.23877?viewType=HTML
work_keys_str_mv AT liyan treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT wuxuanhe treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT shilu treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT liguixia treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT wangshanling treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT wangyating treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT chentailin treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT wangtingting treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT xieyali treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT shenweiwei treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT linhaijiang treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT chenxiaoxiao treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022
AT hena treatmentfailureanddrugresistanceamongthenewlyreportedhivinfectedpatientsintaizhoucityfrom2020to2022